A new ALK inhibitor overcomes resistance to first‐ and second‐generation inhibitors in NSCLC

More than 60% of nonsmall cell lung cancer (NSCLC) patients show a positive response to the first ALK inhibitor, crizotinib, which has been used as the standard treatment for newly diagnosed patients with ALK rearrangement. However, most patients inevitably develop crizotinib resistance due to acqui...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Yue, Fan, Zhenzhen, Zhu, Su‐Jie, Huang, Xiaoxing, Zhuang, Zhongji, Li, Yunzhan, Deng, Zhou, Gao, Lei, Hong, Xuehui, Zhang, Ting, Li, Li, Sun, Xihuan, Huang, Wei, Zhang, Jingfang, Liu, Yan, Zhang, Baoding, Jiang, Jie, Gui, Fu, Wang, Zheng, Li, Qiyuan, Song, Siyang, Huang, Xin, Wu, Qiao, Chen, Lanfen, Zhou, Dawang, Zhang, Jianming, Yun, Cai‐Hong, Chen, Liang, Deng, Xianming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749467/
https://www.ncbi.nlm.nih.gov/pubmed/34845836
http://dx.doi.org/10.15252/emmm.202114296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749467/
https://www.ncbi.nlm.nih.gov/pubmed/34845836
http://dx.doi.org/10.15252/emmm.202114296

Ejemplares similares